{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:48:51Z","timestamp":1780591731552,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011819","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000}}],"reference-count":63,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011819.pub2","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:37:10Z","timestamp":1659094630000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Stem cell transplantation for systemic sclerosis"],"prefix":"10.1002","volume":"2022","author":[{"given":"Sebastian","family":"Bruera","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; Baylor College of Medicine; Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Sidanmat","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine; The University of Texas, MD Anderson Cancer Center; Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A","family":"Molony","sequence":"additional","affiliation":[{"name":"Internal Medicine; UT-Houston Health Science Center; Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen D","family":"Mayes","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunogenetics; The University of Texas at Houston Medical School; Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Suarez-Almazor","sequence":"additional","affiliation":[{"name":"Department of Health Services Research; The University of Texas, MD Anderson Cancer Center; Houston USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Krause","sequence":"additional","affiliation":[{"name":"Research Medical Library; The University of Texas, MD Anderson Cancer Center; Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angeles","family":"Lopez-Olivo","sequence":"additional","affiliation":[{"name":"Department of Health Services Research; The University of Texas, MD Anderson Cancer Center; Houston USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"10.1002\/14651858.CD011819.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantations compared with pulse cyclophosphamide once per months for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0002|cit2","unstructured":"Cyclophosphamide and rATG with hematopoietic stem cell support in systemic scleroderma clinicaltrials.gov\/ct2\/show\/NCT00278525"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0003|cit3","unstructured":"Autologous stem cell systemic sclerosis immune suppression trial (DIScl2011) clinicaltrials.gov\/ct2\/show\/NCT01445821"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0004|cit4","unstructured":"Assassi S Mayes MD Pedroza C Chang JT Furst DE Crofford LJ Immunoablation followed by autologous stem cell transplantation in systemic sclerosis patients decreases significantly the interferon signature 2015 ACR\/ARHP Annual Meeting; 6-11 Nov 2015; San Francisco (CA)"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0005|cit5","first-page":"s272","article-title":"Treatment with myeloablation followed by autologous stem cell transplantation normalizes the systemic sclerosis molecular signature","volume":"3","author":"Assassi","year":"2018","journal-title":"Journal of Scleroderma and Related Disorders"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD011819.pub2-BIB0006|cit6","first-page":"s1002","article-title":"Changes in the systemic sclerosis molecular signatures after myeloablation followed by autologous hematopoietic stem cell transplantation and their clinical correlates","volume":"70","author":"Assassi","year":"2018","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0007|cit7","first-page":"s1213","article-title":"Systemic sclerosis has a distinct serum protein profile that correlates with its clinical manifestations","volume":"70","author":"Bellocchi","year":"2018","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0008|cit8","first-page":"s1100","article-title":"Myeloablation followed by autologous stem cell rescue leads to normalisation of serum IL-6 levels in patients with systemic sclerosis","volume":"77","author":"Bellochi","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0009|cit9","first-page":"s2091","article-title":"Machine learning classification of peripheral blood gene expression identifies a subset of patients with systemic sclerosis most likely to show clinical improvement in response to hematopoietic stem cell transplant","volume":"70","author":"Franks","year":"2018","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0010|cit10","first-page":"s1005","article-title":"Changes in quantitative scleroderma lung CT measures in patients treated with cyclophosphamide or transplantation","volume":"70","author":"Goldin","year":"2018","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0011|cit11","unstructured":"Scleroderma: Cyclophosphamide Or Transplantation (SCOT) clinicaltrials.gov\/ct2\/show\/NCT00114530"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.bbmt.2017.01.012","article-title":"Myeloablative autologous transplantation of CD34+ selected hematopoietic stem cells (HSCT) vs monthly intravenous cyclophosphamide (CY) for severe scleroderma with internal organ involvement: outcomes of a randomized North American clinical trial","volume":"23","author":"Sullivan","year":"2017","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011819.pub2-BIB0013|cit13","first-page":"S21","article-title":"Myeloablative autologous transplantation of CD34+-selected hematopoietic stem cells (HSCT) vs monthly intravenous cyclophosphamide (CYC) for severe scleroderma with internal organ involvement: outcomes of a randomized North American clinical trial [abstract]","volume":"68","author":"Sullivan","year":"2016","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41409-021-01355-1","article-title":"Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score","volume":"56","author":"Abdallah","year":"2021","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/annrheumdis-2012-eular.1962","article-title":"LB0002.\u2005The ASTIS trial: autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results","volume":"71","author":"Laar","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"24","key":"10.1002\/14651858.CD011819.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis","volume":"311","author":"Laar","year":"2014","journal-title":"JAMA"},{"issue":"S10","key":"10.1002\/14651858.CD011819.pub2-BIB0018|cit18","first-page":"4167","article-title":"High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis","volume":"64","author":"Laar","year":"2012","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0019|cit19","unstructured":"Upfront autologous HSCT versus immunosuppression in early diffuse cutaneous systemic sclerosis (UPSIDE) clinicaltrials.gov\/ct2\/show\/NCT04464434"},{"issue":"5","key":"10.1002\/14651858.CD011819.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","author":"American College of Rheumatology","year":"1980","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CLEP.S191418","article-title":"Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease","volume":"11","author":"Bergamasco","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"6","key":"10.1002\/14651858.CD011819.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/ard.60.6.577","article-title":"Phase I\/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease","volume":"60","author":"Binks","year":"2001","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0023|cit23","unstructured":"Visual Rx 2.0 NNT calculator Cates C Dr Chris Cates EBM 2008"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0024|cit24","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from \u00a0training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"6","key":"10.1002\/14651858.CD011819.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/art.23718","article-title":"Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis","volume":"59","author":"Distler","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD011819.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0027|cit27","unstructured":"EndNote X9 Clarivate Analytics 2019"},{"issue":"3","key":"10.1002\/14651858.CD011819.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1046\/j.1365-2141.2002.03895.x","article-title":"Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French Multicentre phase I-II study","volume":"119","author":"Farge","year":"2002","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0029|cit29","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0030|cit30","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2\/"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0031|cit31","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"106","key":"10.1002\/14651858.CD011819.pub2-BIB0032|cit32","first-page":"198","article-title":"Autologous stem cell transplantation in systemic sclerosis: a systematic review","volume":"35","author":"Host","year":"2017","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaut.2013.11.004","article-title":"Diagnostic criteria of systemic sclerosis","volume":"48-49","author":"Hudson","year":"2014","journal-title":"Journal of Autoimmunity"},{"issue":"8","key":"10.1002\/14651858.CD011819.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/rheumatology\/keu530","article-title":"Performance of the new ACR\/EULAR classification criteria for systemic sclerosis in clinical practice","volume":"54","author":"Jordan","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1002\/14651858.CD011819.pub2-BIB0035|cit35","first-page":"971","article-title":"Reliability and minimal clinically important differences of FVC results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2017","journal-title":"Journal of Respiratory and Critical Care Medicine"},{"issue":"10","key":"10.1002\/14651858.CD011819.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3899\/jrheum.090372","article-title":"Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)","volume":"36","author":"Khanna","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-019-1809-y","article-title":"Minimal clinically important differences for the modified Rodnan Skin Score: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"21","author":"Khanna","year":"2019","journal-title":"Arthritis Research and Therapy"},{"issue":"5","key":"10.1002\/14651858.CD011819.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD011819.pub2-BIB0039|cit39","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD011819.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis and Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD011819.pub2-BIB0041|cit41","first-page":"1630","article-title":"Current status of outcome measure development of clinical trials in systemic sclerosis. Report from OMERACT 6","volume":"30","author":"Merkel","year":"2003","journal-title":"Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD011819.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/rheumatology\/keu285","article-title":"Old medications and new targeted therapies in systemic sclerosis","volume":"54","author":"Nagaraja","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1002\/14651858.CD011819.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood-2007-02-072389","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study","volume":"110","author":"Nash","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD011819.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1705782","article-title":"Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis","volume":"40","author":"Oyama","year":"2007","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0045|cit45","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"1","key":"10.1002\/14651858.CD011819.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13075-015-0594-5","article-title":"Application of the 2013 ACR\/EULAR classification criteria for systemic sclerosis to patients with Raynaud's phenomenon","volume":"17","author":"Park","year":"2015","journal-title":"Arthritis Research & Therapy"},{"issue":"8","key":"10.1002\/14651858.CD011819.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00296-011-1967-y","article-title":"Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis","volume":"32","author":"Poormoghim","year":"2012","journal-title":"Rheumatology International"},{"issue":"4","key":"10.1002\/14651858.CD011819.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/rheumatology\/kez300","article-title":"Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant - a systematic review","volume":"59","author":"Puyade","year":"2019","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0049|cit49","unstructured":"Review Manager 5 (RevMan 5) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0050|cit50","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD011819.pub2-BIB0051|cit51","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"3","key":"10.1002\/14651858.CD011819.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3899\/jrheum.090375","article-title":"The minimally important difference in clinical practice for patient-centered outcomes including Health Assessment Questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma","volume":"37","author":"Sekhon","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD011819.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","article-title":"Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis","volume":"24","author":"Shouval","year":"2018","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD011819.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bmt.2011.185","article-title":"Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation","volume":"47","author":"Snowden","year":"2012","journal-title":"Bone Marrow Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD011819.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/rheumatology\/keab604","article-title":"Outcomes linked to eligibility for stem cell transplantation trials in diffuse systemic cutaneous systemic sclerosis","volume":"61","author":"Spierings","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1002\/14651858.CD011819.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD011819.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffuse scleroderma","volume":"43","author":"Steen","year":"2000","journal-title":"Arthritis and Rheumatism"},{"issue":"25","key":"10.1002\/14651858.CD011819.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011819.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respiratory Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011819.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.reuma.2012.05.006","article-title":"A meta-analysis of mortality in rheumatic diseases","volume":"8","author":"Toledano","year":"2012","journal-title":"Reumatologia Clinica"},{"issue":"11","key":"10.1002\/14651858.CD011819.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"den Hoogen","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD011819.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/01.bor.0000434669.32150.ac","article-title":"Stem cell transplantation in systemic sclerosis","volume":"25","author":"Laar","year":"2013","journal-title":"Current Opinion in Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD011819.pub2-BIB0063|cit63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011819","article-title":"Stem cell transplantation for systemic sclerosis","author":"Bruera","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T13:49:39Z","timestamp":1699537779000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011819.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":63,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011819.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]}}}